Cancer Genetics, Inc.
| NASDAQ: CGIX | Healthcare / Medical Laboratories & Research / USA |
| 0.1700 | +0.0100 | +6.25% | Vol 796 052 | 1Y Perf -82.79% |
| Jun 20th, 2019 15:59 |
| BID | 0.1700 | ASK | 0.1700 | ||
| Open | 0.1700 | Previous Close | 0.1600 | ||
| Pre-Market | 0.17 | After-Trading | - | ||
| 0.01 6.25% | - -% |
| Target Price | 4.50 | Analyst Rating | — 0.00 | |
| Potencial % | 2 547.06 | Finscreener Ranking | ★ — - | |
| Insiders Trans % 3/6/12M | -/100/100 | Value Ranking | ☆ 26.78 | |
| Insiders Value % 3/6/12M | -/100/100 | Growth Ranking | ☆ 27.98 | |
| Insiders Shares Cnt. % 3/6/12M | -/100/100 | Income Ranking | — - | |
| Market Cap (mil) | 10 | Earnings Rating | Buy | |
| Price Range Ratio 52wk % | 1.74 | Earnings Date | 13th Aug 2019 |
Today's Price Range 0.16000.1700 | 52wk Range 0.15001.30 |
Summary:
Buy
| Technical Indicators: | Buy |
| Moving Averages: | Strong Buy |
| Performance | |||
|---|---|---|---|
| 1 Month | 0.00% | ||
| 3 Months | -37.04% | ||
| 6 Months | -51.43% | ||
| 1 Year | -82.79% | ||
| 3 Years | -91.46% | ||
| 5 Years | -98.48% |
| Management Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
Return on Equity (5Y Avg) | -14.17 | |||
ROE last 12 Months | -158.28 | |||
Return on Assets (5Y Avg) | -9.86 | |||
ROA last 12 Months | -50.83 | |||
Return on Capital (5Y Avg) | -49.64 | |||
ROC last 12 Months | -64.33 | |||
Return on invested Capital Q | -14.21 | |||
Return on invested Capital Y | -64.79 | |||
Assets Turnover | 0.60 | |||
Receivables Turnover | 3.00 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
PE Ratio | - | |||
PB Ratio | 1.27 | |||
PS Ratio | 0.37 | |||
Price to Cash Flow | - | |||
Price to Free Cash Flow | -0.90 | |||
Cash Flow Per Share | -0.38 | |||
Price to Tangible Book | -0.72 | |||
Book Value per Share | 0.13 | |||
Enterprise Value (in ths.) | 23 509 |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
Quick Ratio | 0.30 | |||
Current Ratio | 0.40 | |||
Long Term Debt to Total Capital | 0.19 | |||
Total Debt to Equity | 1.88 | |||
Interest Coverage | -4.70 | |||
| Leverage Ratio | 3.80 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
Gross Margin | 31.40 | |||
EBIT Margin | -63.50 | |||
EBITDA Margin | -56.40 | |||
Pre-tax Profit Margin | -103.20 | |||
Profit Margin | -76.99 |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
Revenue LTM (in ths.) | 26 642 | |||
Revenue per Share | 0.46 | |||
Revenue Growth 3 Years | 8.01 | |||
Revenue Growth 5 Years | 30.56 |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
Dividend Yield | - | |||
Dividend Rate | - | |||
Dividend Growth 3 Years | - | |||
Dividend Growth 5 Years | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q01 2019 | - | -0.08 | - |
| Q04 2018 | - | -0.14 | - |
| Q03 2018 | -0.16 | -0.23 | -43.75 |
| Q02 2018 | -0.13 | -0.13 | 0.00 |
| Q01 2018 | - | -0.16 | - |
| Q04 2017 | - | -0.35 | - |
| Q03 2017 | -0.13 | -0.16 | -23.08 |
| Q02 2017 | -0.16 | -0.16 | 0.00 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 3/2019 QR | -0.07 | 0.00 | - |
| 6/2019 QR | -0.05 | 0.00 | - |
| 12/2019 FY | -0.11 | 0.00 | - |
| 12/2019 FY | -0.11 | - | - |
| Next Report Date | 13th Aug 2019 |
| Estimated EPS Next Report | - |
| Estimates Count | - |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 796 052 |
| Shares Outstanding (in ths.) | 57 816 |
| Trades Count | 607 |
| Dollar Volume | 131 895 |
| Avg. Volume | 1 900 105 |
| Avg. Weekly Volume | 642 129 |
| Avg. Monthly Volume | 1 018 572 |
| Avg. Quarterly Volume | 1 474 555 |
Cancer Genetics, Inc.
Cancer Genetics Inc is in the early stage of precision medicine, enabling individualized therapies in the field of oncology through diagnostic products and services and molecular markers. The company develops, commercializes and provides molecular- and biomarker-based tests and services that enable physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor and inform cancer treatment. It also enables biotech and pharmaceutical companies to select candidate populations and reduce adverse drug reactions by providing information regarding genomic factors influencing subject responses to therapeutics. The company derives most of its revenue from the United States.
CEO: John A. Roberts
Teplephone: +1 201 528-9200
Address: 201 Route 17 North, Rutherford 07070, NJ, USA
